RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Recruiting
Observational Study
Sickle Cell Disease
Thalassemia
Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder
Anemia Due to Membrane Defect
CDA
Sideroblastic Anemia
Constitutional Aplastic Anemia
Iron Metabolism Disorders
Hereditary Anemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 0 – 100
- Sex
- Any
- Study type
- Observational
- Participants needed
- 32,564 (estimated)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and thei…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients must meet all of the following criteria to be included in the RADeep Registry
* Age from 0-100, both female and male
* Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANET classification)
* Able and willing to provide written informed consent (…
Contacts